Search - tctmd.com

Displaying 901 - 920 of 10338

Sort: Relevancy | Date

Presentation TCT 2016

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Presenter: Raj Makkar, Lars Sondergaard, Axel Linke

October 31, 2016

Egypt Responds: How Would I Have Treated This Case in My Cath Lab?

Presentation TCT 2016

Egypt Presents: A Case of a Challenging Bifurcation Intervention: How Did I Treat?

Presenter: Mohammad Al-Mutairi, Ricardo Lluberas, Ahmed Magdy, Jorge Villegas, Robaayah Zambahari, Sameh Shaheen

October 31, 2016

Presentation TCT 2016

Public Reporting, Appropriateness Criteria, and the CHIP Initiative: At Odds or Working Together?

Presenter: Emmanouil S. Brilakis, Jeffrey W. Moses, Robert W. Yeh

October 31, 2016

Presentation TCT 2016

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

Presenter: Owen Faris, Mitchell W. Krucoff, Michael R Minogue

October 31, 2016

Presentation TCT 2016

ABSORB III Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Ron Waksman

October 31, 2016

Presentation TCT 2016

What Have We Learned From Contemporary Left Main Observational Studies I? French and LEMAX Registries

Presenter: Seung-Jung Park, Leif Thuesen, Philippe Garot

October 31, 2016

Presentation TCT 2016

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing II: Biomechanical Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada

October 31, 2016

Presentation TCT 2016

Can Transcatheter Mitral Annuloplasty Provide a Long-term Solution for Secondary MR: Implications of the CTSN SMR Trial and Other Experiences

Presenter: Ted Feldman, Scott Lim, Steven F. Bolling

October 31, 2016

Presentation TCT 2016

Malaysia Responds: How Would I Have Treated This Case in My Cath Lab?

Presenter: Mohammad Al-Mutairi, Ricardo Lluberas, Ahmed Magdy, Jorge Villegas, Robaayah Zambahari

October 31, 2016

Presentation TCT 2016

Why I Became a CTO Operator and What It Means to Me

Presenter: James C. Spratt, Simon J. Walsh, Nicholas J. Lembo

October 31, 2016

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

Presentation TCT 2016

The Worldwide Epidemic of Peripheral Artery Disease, and Medical Interventions Which Really Work

Presenter: Tony Das, Koen Deloose, Ido Weinberg

October 31, 2016

Presentation TCT 2016

Primary PCI in Patients With Multivessel Disease: Overview of Randomized Trials and Unanswered Questions

Presenter: Ran Kornowski, Michel R. Le May, Kevin Bainey

October 31, 2016

Presentation TCT 2016

Obstacles for Clinical Research: The BAMI Experience

Presenter: Emerson C. Perin, Ricardo Sanz-Ruiz

October 31, 2016

Presentation TCT 2016

Next Generation MitraClip: Whats Better and Whats Not

Presenter: Ted Feldman, Scott Lim, Ralph Stephan von Bardeleben

October 31, 2016

Presentation TCT 2016

Left Main PCI vs CABG From the Asan Medical Center: Insights Into Patient Selection and Technique to Optimize Outcomes

Presenter: Seung-Jung Park, Leif Thuesen

October 31, 2016

Presentation TCT 2016

Introductory Lecture: Defining CHIP/Complex PCI in 2016 - Where We Are and Where We Need to Go

Presenter: Emmanouil S. Brilakis, Jeffrey W. Moses

October 31, 2016

Presentation TCT 2016

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing I: Pathologic Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada, Renu Virmani

October 31, 2016

Presentation TCT 2016

Endovascular Intervention II: Popliteal, BTK and Carotid

Presenter: Prakash Krishnan, Karthik R. Gujja

October 31, 2016

Presentation TCT 2016

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Presenter: Raj Makkar, Lars Sondergaard, Samir R. Kapadia

October 31, 2016

Advertisement

Flash Debate: Point Cerebral Protection Is a Must for All Patients!

Egypt Presents: A Case of a Challenging Bifurcation Intervention: How Did I Treat?

Public Reporting, Appropriateness Criteria, and the CHIP Initiative: At Odds or Working Together?

MDIC and Industry Perspectives: Potential Effects of NEST on Research, Innovation and Patient Outcomes

ABSORB III Critique: Pros and Cons

What Have We Learned From Contemporary Left Main Observational Studies I? French and LEMAX Registries

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing II: Biomechanical Perspectives

Can Transcatheter Mitral Annuloplasty Provide a Long-term Solution for Secondary MR: Implications of the CTSN SMR Trial and Other Experiences

Malaysia Responds: How Would I Have Treated This Case in My Cath Lab?

Why I Became a CTO Operator and What It Means to Me

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

The Worldwide Epidemic of Peripheral Artery Disease, and Medical Interventions Which Really Work

Primary PCI in Patients With Multivessel Disease: Overview of Randomized Trials and Unanswered Questions

Obstacles for Clinical Research: The BAMI Experience

Next Generation MitraClip: Whats Better and Whats Not

Left Main PCI vs CABG From the Asan Medical Center: Insights Into Patient Selection and Technique to Optimize Outcomes

Introductory Lecture: Defining CHIP/Complex PCI in 2016 - Where We Are and Where We Need to Go

Implications of Bioresorbable Polymer/Metal Type, Processing, Thickness, Configuration, and Other Variables on Mechanical Properties, Vascular Compatibility, and Healing I: Pathologic Perspectives

Endovascular Intervention II: Popliteal, BTK and Carotid

Controversy 1. Is Cerebral Embolic Protection Needed for TAVR? The Evidence: Observations From DEFLECT 3, CLEAN-TAVI, and the SENTINEL Clinical Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content